Saturday 17 October 2026
Export ADVB’s income statement to Excel — free account
Advanced Biomed Inc.
ADVB Healthcare Diagnostics & Research
Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00. In the quarter to June 2026, EPS grew 54.8% and free cash flow fell 101.3%, each against the same quarter a year earlier.
3.98
0.90
−18.44%
Follow ADVB
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to June
| Group | Line | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Trend | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | — | 5.60 | 3.61 |
Analyst estimates 2027–2029 Powerpack |
|||
| High | — | — | — | — | — | — | — | — | 82.00 | 24.23 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 40 | 31 | 18 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.01 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | 0 | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | 100.00 | |||||
| EBT | — | — | — | — | — | — | — | (3) | (1) | (6) | |||||
| EBT margin, % | — | — | — | — | — | — | — | 0.00 | 0.00 | (4,907.92) | |||||
| Net income | — | — | — | — | — | — | — | (3) | (3) | 7 | |||||
| Depreciation | — | — | — | — | — | — | — | 0 | 0 | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.10 | ||||
| Earnings | — | — | — | — | — | — | — | (2.78) | (3.20) | 5.33 | |||||
| Cash flow | — | — | — | — | — | — | — | (2.13) | (5.68) | (1.55) | |||||
| Capex | — | — | — | — | — | — | — | (0.07) | (0.03) | (2.06) | |||||
| Free cash flow | — | — | — | — | — | — | — | (2.20) | (5.71) | (3.61) | |||||
| Book value | — | — | — | — | — | — | — | 1.66 | 3.39 | 9.80 | |||||
| Shares, m | — | — | — | — | — | — | — | 1 | 1 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | 0.90 | ||||
| P/S | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| P/B | — | — | — | — | — | — | — | — | — | 0.47 | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | 0.00 | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | (1.20) | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | — | — | (2) | (6) | (2) | ||||
| Capex | — | — | — | — | — | — | — | 0 | 0 | (3) | |||||
| Free cash flow | — | — | — | — | — | — | — | (2) | (6) | (5) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | — | — | 0 | 3 | 12 | ||||
| Total debt | — | — | — | — | — | — | — | — | — | — | |||||
| Net debt | — | — | — | — | — | — | — | (3) | 0 | 0 | |||||
| Shareholders’ equity | — | — | — | — | — | — | — | 2 | 3 | 12 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | — | — | 0.00 | (23.86) | 36.47 | ||||
| ROIC | — | — | — | — | — | — | — | 0.00 | (19.70) | (32.76) | |||||
| ROE | — | — | — | — | — | — | — | 0.00 | (126.79) | 84.77 | |||||
Negative figures in brackets.
Fiscal years to Jun 2026 · fundamentals updated 15 Oct 2026
Charts ten years each
Advanced Biomed Inc. vs peers in Diagnostics & Research (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| PMD Psychemedics Corporation | $15.7M | — (loss-making) | — (loss-making) | −11.46% (below 0%: shrinking) | n/m | +57.45% (above 0%: growing) | 31.37% | 3.80% | Compare |
| ADVB Advanced Biomed Inc. | $8.1M | 0.8× | — | — | n/m | −101.33% (below 0%: shrinking) | — | 0.00% | |
| NDRA ENDRA Life Sciences Inc. | $7.7M | — (loss-making) | — (loss-making) | −98.80% (below 0%: shrinking) | n/m | +15.04% (above 0%: growing) | 0.00% | 0.00% | Compare |
| XWEL XWELL, Inc. | $7.5M | — (loss-making) | — (loss-making) | −7.08% (below 0%: shrinking) | n/m | −43.02% (below 0%: shrinking) | 41.26% | (29.45%) | Compare |
| TTOO T2 Biosystems, Inc. | $6.5M | — (loss-making) | — (loss-making) | +34.85% (above 0%: growing) | n/m | +53.36% (above 0%: growing) | (106.60%) | (511.89%) | Compare |
| BIAF bioAffinity Technologies, Inc. | $5.1M | — (loss-making) | — (loss-making) | +18.99% (above 0%: growing) | n/m | −23.69% (below 0%: shrinking) | 27.98% | (220.77%) | Compare |
| DMTKQ DermTech, Inc. | $3.3M | — (loss-making) | — (loss-making) | +10.58% (above 0%: growing) | n/m | +24.87% (above 0%: growing) | 18.54% | (533.37%) | Compare |
| NOTVQ Inotiv, Inc. | $2.8M | — (loss-making) | — (loss-making) | −5.37% (below 0%: shrinking) | n/m | +82.66% (above 0%: growing) | 20.95% | (16.41%) | Compare |
| ISPC iSpecimen Inc. | $2.6M | — (loss-making) | — (loss-making) | −78.70% (below 0%: shrinking) | n/m | −257.73% (below 0%: shrinking) | 45.23% | (897.30%) | Compare |
| Median of peers | $5.8M | — | — | −6.22% | — | +19.96% | 24.46% | (125.11%) |
Advanced Biomed Inc. (ADVB) key facts
- Advanced Biomed Inc. (ADVB) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
- Advanced Biomed Inc.’s revenue for fiscal 2026 (year ended June 2026) was $127,600.00.
- As of October 16, 2026, ADVB traded at $3.98, a market capitalization of $8.1 million.
- Return on equity was 84.8% and debt-to-equity 0.00.
- Its Altman Z-score is 0.68 (distress zone) for fiscal 2026.